Lupin has been featured for the first time in the Dow Jones Best-in-Class (DJBIC) Indices, underscoring the company’s strong commitment to sustainable, responsible, and ethical business practices. The company has been listed in both the DJBIC World Index and the DJBIC Emerging Markets Index.
The DJBIC World Index ranks top-performing companies globally by strong Environmental, Social, and Governance (ESG) performance, while the DJBIC Emerging Markets Index highlights sustainability leaders across emerging economies. The company was previously ranked among the top 1% globally in the S&P Global Corporate Sustainability Assessment (CSA) 2025, achieving an industry-leading score of 91/100.
The DJBIC Indices recognize companies that demonstrate exceptional performance across key ESG parameters, based on leading S&P Global CSA scores. Inclusion in these prestigious indices reinforces the company’s credibility with global investors, strengthens its competitive positioning, and places the company among a distinguished group of global leaders recognized for best-in-class sustainability performance.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
